Volume 3.45 | Nov 17

Human Immunology News 3.45 November 17, 2015
Human Immunology News
     In this issue: Publications | Reviews | Science News | Industry News | Policy News | Events | Jobs
Like Us on Facebook  HIN on Twitter
 
TOP STORY
Lenalidomide plus Rituximab Produces Durable Responses in Mantle Cell Lymphoma Patients in Phase II Study
Researchers assessed the combination of lenalidomide plus rituximab in patients with mantle cell lymphoma who had not received prior treatment. The patients received the combination treatment for approximately a year followed by a period of low-dose treatment for up to three years to maintain an anti-tumor response. [Press release from Moffitt Cancer Center discussing online publication in The New England Journal of Medicine] Press Release | Abstract
It all starts with the right cells! Get Fresh Human Peripheral Whole Blood and Leuko Paks
 
PUBLICATIONS (Ranked by impact factor of the journal)
A Validated Gene Regulatory Network and GWAS Identifies Early Regulators of T Cell–Associated Diseases
Researchers identified early regulators of T cell–mediated disease by finding transcription factors involved in T cell differentiation that are enriched in disease-associated polymorphisms. [Sci Transl Med] Abstract

IL-36α: A Novel Cytokine Involved in the Catabolic and Inflammatory Response in Chondrocytes
OA chondrocytes expressed more IL-36α than healthy chondrocytes. Immune cells infiltrated into the joint and PBMCs expressed higher levels of IL-36α in comparison to chondrocytes. [Sci Rep] Full Article

Analysis of the Secretome of Apoptotic Peripheral Blood Mononuclear Cells: Impact of Released Proteins and Exosomes for Tissue Regeneration
The authors previously showed that, when peripheral blood mononuclear cells (PBMCs) were stressed with ionizing radiation, they released paracrine factors that showed regenerative capacity in vitro and in vivo. In this study, they aimed to characterize the secretome of PBMCs and to investigate its biologically active components in vitro and in vivo. [Sci Rep] Full Article

CD40 Ligand-Expressing Recombinant Vaccinia Virus (rVV40L) Promotes the Generation of CD8+ Central Memory T Cells
Scientists generated a replication incompetent CD40 ligand-expressing recombinant vaccinia virus to promote the differentiation of human naïve CD8+ T cells into central memory CD8+ T cells specific for viral and tumor associated antigens. [Eur J Immunol] Abstract

Combination of Cytokine-Induced Killer and Dendritic Cells Pulsed with Antigenic α-1,3-Galactosyl Epitope–Enhanced Lymphoma Cell Membrane for Effective B-Cell Lymphoma Immunotherapy
Incubation of processed cell membranes with autologous dendritic cells (DCs) in the presence of human serum containing abundant natural anti–α-1,3-galactosyl immunoglobulin G led to the effective phagocytosis of tumor membranes by DCs. [Cytotherapy] Abstract

miR-27a and miR-214 Exert Opposite Regulatory Roles in Th17 Differentiation via Mediating Different Signaling Pathways in Peripheral Blood CD4+ T Lymphocytes of Patients with Relapsing–Remitting Multiple Sclerosis
Researchers assessed transcript levels of miR-27a and miR-214, in purified CD4+ T cells of multiple sclerosis patients, during relapsing and remitting phases in inducing differentiation of T naïve cells to T helper 17 (Th17) cells. [Immunogenetics] Abstract

Profiling of Primary Peripheral Blood- and Monocyte-Derived Dendritic Cells Using Monoclonal Antibodies from the HLDA10 Workshop in Wollongong, Australia
Scientists compared the reactivity patterns of HLDA10 antibodies with plasmacytoid dendritic cells (DCs), CD1c+ DCs and CD141+ DCs, as well as with CD14+-derived monocyte-derived DCs cultured for seven days in the presence of granulocyte–macrophage colony-stimulating factor plus interleukin-4. [Clin Transl Immunol] Full Article

Myeloid Cells as Target of Fingolimod Action in Multiple Sclerosis
In vitro and ex vivo immunologic studies coupled with flow cytometry were performed to evaluate the action of fingolimod on lipopolysaccharide–induced expression of activation markers in human monocytes from healthy participants, participants with untreated multiple sclerosis (MS), and participants with fingolimod-treated MS. [Neuroimmunol Neuroinflamm] Full Article | Editorial

Subscribe to our sister publications: Immunology of Infectious Disease News & Immune Regulation News!

Isolate particle-free human CD4+CD127lowCD25+ regulatory T cells (Tregs) in less than one hour. Request a sample today.
 
REVIEWS
Innate Immunity in Diabetes and Diabetic Nephropathy
The authors describe how innate immune system-driven inflammatory processes can lead to apoptosis, tissue fibrosis, and organ dysfunction resulting in insulin resistance, impaired insulin secretion, and renal failure. [Nat Rev Nephrol] Abstract

Visit our reviews page to see a complete list of reviews in the Human Immunology research field.
 
SCIENCE NEWS
Positive CAVATAK™ Clinical Data Presented
Viralytics Limited announced positive data from two clinical studies of its lead drug candidate CAVATAK™. CAVATAK is an investigational novel cancer immunotherapy based on a proprietary bioselected common cold virus that has been shown to preferentially infect and attack cancer cells. [Press release from Viralytics Limited discussing research presented at the 30th Annual Meeting of the Society for the Immunotherapy of Cancer (SITC), National Harbor] Press Release

Kineta Presents New Data Demonstrating Positive, Predictive Responses to Dalazatide in Psoriasis Patients and in Lupus, ANCA Vasculitis Studies
Kineta, Inc. presented new, positive dalazatide data from its recent Phase Ib active plaque psoriasis clinical trial as well as encouraging dalazatide research in lupus from its collaboration with Seattle Children’s Research Institute and in ANCA Vasculitis from its study with the University of Groningen. [Press release from Kineta, Inc. discussing research presented at the 2015 ACR/ARHP Annual Meeting, San Francisco] Press Release

From our sponsor: Working with blood? Download the immune cell frequencies app.
 
INDUSTRY NEWS
Targazyme and University of Minnesota Medical Center Initiate a Collaboration to Improve Regulatory T Cell Immunotherapy Outcomes for the Prevention and Treatment of Graft-versus-Host-Disease
Targazyme, Inc. announced that it has entered into a collaboration with the University of Minnesota Medical Center to advance the development of the company’s clinical product candidate, TZ101 for use with regulatory T cells. [Targazyme, Inc.] Press Release

Bavarian Nordic Announces Results of a Phase I Trial Investigating Brachyury Specific Cancer Vaccine in Patients with Advanced Cancer
Bavarian Nordic A/S announced results from an NCI-sponsored Phase I study investigating its novel cancer vaccine, MVA-BN® Brachyury. Data from this study demonstrate for the first time that an MVA-BN based vaccine targeting brachyury can induce brachyury-specific T-cell immune responses in advanced cancer patients. [Bavarian Nordic A/S] Press Release

Celltrion Submits Second Biosimilar for Approval to European Regulator
Celltrion announced that it filed a request for European Medicines Agency approval of CT-P10. CT-P10 is a candidate biosimilar of rituximab, which is used to treat hematological cancer, rheumatoid arthritis and transplant rejection. [Celltrion Inc. (BusinessKorea Co., Ltd.)] Press Release

CEL-SCI IS Granted a New European Patent on Its Phase III Investigational Cancer Immunotherapy Multikine
CEL-SCI Corporation announced that it has been granted a European patent on Multikine, its investigational Phase III cancer immunotherapy. [CEL-SCI Corporation] Press Release
 
POLICY NEWS
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
 
EVENTS
NEW Cell & Gene Therapy World
January 25-27, 2016
Washington DC, United States

Visit our events page to see a complete list of events in the Human Immunology community.
 
JOB OPPORTUNITIES
NEW Research Technician – Preclinical and Translational Research (Qu Biologics Inc.)

NEW Postdoctoral Fellow – Immunology (Medical College of Wisconsin)

NEW Postdoctoral Fellow – Transplantation Immunology (H. Lee Moffitt Cancer Center & Research Institute)

Senior Scientist – Immunology and Cell Separation (STEMCELL Technologies Inc.)

Assistant Professor – Cancer Immunology (Children’s Hospital of Philadelphia)

Postdoctoral Position – Immunology and Cell Biology (Beth Israel Deaconess Medical Center)

Staff Scientist – Immunology (Benaroya Research Institute at Virginia Mason)

Postdoctoral Research Fellow – Molecular Oncology (Genentech, Inc.)

Professor – Immunology (La Jolla Institute for Allergy & Immunology)

Principal Investigator – The Role of Inflammation and the Immune Response in Regenerative Medicine (KU Leuven)


Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
 

Have we missed an important article or publication in Human Immunology News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Human Immunology News: Archives | Events | Contact Us